Comparative Pharmacology
Head-to-head clinical analysis: LUMIZYME versus NAGLAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIZYME versus NAGLAZYME.
LUMIZYME vs NAGLAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
5 mg/kg administered intravenously once every 2 weeks.
1 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy